ClinicalTrials.gg
Not yet recruitingNCT07453979Updated Mar 6, 2026

AI-Supported Video Education in Episiotomy Care

An interventional study of Control and AI-Assisted Episiotomy Care Video Group in Postpartum Perineal Pain, sponsored by Burdur Mehmet Akif Ersoy University. Not yet recruiting. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Burdur Mehmet Akif Ersoy University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Although the postpartum period is generally considered a positive experience, obstetric interventions such as episiotomy may lead to significant maternal health problems. Episiotomy, a surgical incision performed on the perineum during the second stage of labor, remains widely used despite World Health Organization recommendations to limit its rate. Episiotomy-related complications, including pain, infection, bleeding, and dyspareunia, can negatively affect wound healing, quality of life, and postpartum sexual health. Proper episiotomy wound care and education are therefore essential components of postpartum care. This study aims to evaluate the effect of an artificial intelligence-supported video education on episiotomy wound healing and postpartum sexual quality of life. The findings are expected to contribute to improved postpartum care practices and guide future research in this field.

Read the detailed description

Although the postpartum period is generally considered a positive experience for mothers, obstetric interventions such as episiotomy may lead to various health problems. Episiotomy, defined as a strategic surgical incision made in the perineum during the second stage of labor, remains a fundamental obstetric intervention (WHO, 2018). Despite the World Health Organization's recommendation to reduce episiotomy rates in normal vaginal births to 10%, this procedure is still performed in approximately 30-50% of women (WHO, 2018), and post-episiotomy perineal discomfort has been reported in 42% of women (Roma et al., 2023).

Episiotomy may result in bleeding, infection, and postpartum pain associated with an increased risk of dyspareunia, thereby negatively affecting women's quality of life and sexual health (Hartinah et al., 2021). Minimizing these adverse outcomes requires preventing chronic pain, supporting mothers in effective pain management, preventing constipation, monitoring urinary retention, and reducing the risk of infection (Hartinah et al., 2021).

Evidence indicates that keeping the episiotomy wound dry, compared with sitz baths, reduces postpartum pain, accelerates wound healing, and positively influences postpartum sexual function (Alirezaei et al., 2024; Roma et al., 2023; Brezeanu et al., 2025; Aydemir et al., 2024). Therefore, education on episiotomy wound care constitutes a critical component of postpartum care.

The aim of this study is to evaluate the effect of an artificial intelligence-supported video education on episiotomy wound healing and postpartum sexual quality of life. Additionally, the study seeks to determine the impact of AI-supported video education on episiotomy wound healing, pain, and dyspareunia among postpartum women and to provide a foundation for future research in this field.

02

Conditions studied

  • Postpartum Perineal Pain

Browse trials for

Keywords

  • Episiotomy
  • Postpartum Care
  • Artificial Intelligence
  • Wound Healing
  • Sexual Quality of Life
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 70 is close to the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Burdur Mehmet Akif Ersoy University is the lead sponsor of 48 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

18 years of age and older,

  • No high-risk pregnancy (no systemic disease, no smoking, no postpartum complications),
  • Gestational age 37-42 weeks,
  • Single vaginal delivery of live birth,
  • Mediolateral episiotomy,
  • Not taking any medication,
  • No other lacerations besides episiotomy (anal sphincter injury, 3rd degree perineal laceration).
  • Single vaginal delivery of live birth or single vaginal delivery without episiotomy, age between 18-35 years, sexually active and healthy
  • Primiparous pregnant women

Exclusion criteria

Exclusion Criteria:

    • Mothers who have had multiple, stillbirth, or anomalous births,

      • Mothers who refuse home visits will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    INTERVENTION 1

    Women allocated to the intervention group will receive an AI-assisted video-based educational intervention on episiotomy care in addition to routine postpartum care.

    Behavioral: AI-Assisted Episiotomy Care Video Group

  • Other
    Control

    Routine postpartum care

    Other: Control

Interventions

  • OtherControl

    Women in the control group will receive routine postpartum and episiotomy care provided by midwives before discharge, in accordance with standard hospital practices. No additional educational or AI-assisted video intervention will be provided to this group.

  • BehavioralAI-Assisted Episiotomy Care Video Group

    Women in the intervention group will receive routine postpartum care and an AI-assisted educational video about effective breastfeeding within the first 30 minutes after birth. The video includes information on the importance of early breastfeeding, correct breastfeeding positions, and techniques to increase milk production.

06

What researchers measure

Primary outcomes

  1. (REEDA Scale)

    Episiotomy wound healing will be evaluated using the REEDA Scale, which assesses five components: redness, edema, ecchymosis, discharge, and approximation of wound edges.

    Time frame: Postpartum Day 1, Day 3, Day 5, Day 7, and Day 14

  2. Episiotomy wound healing score (REEDA Scale)

    Episiotomy wound healing will be assessed using the REEDA Scale, which evaluates five components: redness, edema, ecchymosis, discharge, and approximation of wound edges

    Time frame: Postpartum day 1, day 3, day 5, day 7, and day 14

  3. Perineal pain intensity (Visual Analog Scale - VAS)

    Perineal pain intensity will be measured using the Visual Analog Scale (VAS), a 10-cm horizontal line ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will indicate their perceived pain intensity on the scale.

    Time frame: Postpartum day 1, day 3, day 5, day 7, and day 14

Secondary outcomes

  1. Postpartum sexual function and dyspareunia score (Carol Postpartum Sexual Function and Dyspareunia Scale)

    Postpartum sexual function and dyspareunia will be evaluated using the Carol Postpartum Sexual Function and Dyspareunia Scale, which assesses readiness for sexual activity, vulvar discomfort, pain during vaginal intercourse, and pain after intercourse

    Time frame: Postpartum 3 months after resumption of vaginal intercourse

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for May 2026, 1 month later.

Of 3,731 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 1 month is below that.

Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Mar 6, 2026
StartEst.
Apr 2, 2026
Primary completionEst.
May 30, 2026
CompletionEst.
Jul 30, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453979
Lead sponsor
Burdur Mehmet Akif Ersoy University
Responsible party
Mine Gokduman Keles (assistant Prof dr, Kahramanmaras Sutcu Imam University) — Principal investigator
First posted
Mar 6, 2026
Start date
Apr 2, 2026 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Mar 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion